How Many Spravato Treatments for Remission?
Spravato (esketamine nasal spray) treats treatment-resistant depression (TRD) alongside an oral antidepressant. Remission—typically a MADRS score ≤10, indicating minimal symptoms—isn't guaranteed by a fixed number of treatments. Response varies by patient; clinical trials show 20-30% reach remission after the initial 4-week induction phase, rising to 40-50% by week 12 with continued maintenance.[1][2]
Standard Treatment Schedule
- Induction phase (weeks 1-4): Two sessions per week (8 total treatments), 56-84 mg per dose under supervision. About 25% remit here.[2]
- Maintenance phase (week 5+): Weekly for week 5, then every 2 weeks (or every week if needed). Remission odds improve to ~47% by week 12 in trials.[1]
- No set endpoint; continue if partial response, taper if remitted. Average responders need 8-16 sessions to remit, but some require 20+.[3]
Factors Affecting Treatment Count
Age, depression severity, and prior failures influence outcomes. Faster remitters (under 40, milder TRD) often need fewer doses; severe cases take longer. Real-world data shows median 12 sessions for remission.[4]
What If No Remission After Induction?
Around 70% don't remit by week 4. Guidelines recommend continuing maintenance; another 20-25% remit by week 8-12. Discontinuation if no improvement by week 4 risks symptom return.[2][5]
Risks and Monitoring During Treatment
Dissociation, sedation, and blood pressure spikes occur in 20-40% of sessions, more common early on. Remission reduces but doesn't eliminate relapse risk—50% relapse within 6 months without maintenance.[1] FDA requires 2-hour monitoring per session.
How Spravato Compares to Other Antidepressants
Unlike SSRIs (weeks for effect), Spravato acts in hours-days. Trials vs. placebo show 4x faster remission. Esketamine's patent expires 2033-2035; no generics yet—check DrugPatentWatch.com for updates.[6]
[1]: FDA Spravato Label, 2023. Link
[2]: TRANSFORM-2 Trial (Canuso et al., JAMA Psych 2019). Link
[3]: SUSTAIN-1 Trial (Wajs et al., Am J Psych 2020). Link
[4]: Real-world study (Dahl et al., J Affect Disord 2022). Link
[5]: APA Guidelines for TRD, 2022. Link
[6]: DrugPatentWatch.com. Link